Phase II trial of HLP004 for the treatment of Generalized anxiety disorder.
Latest Information Update: 09 Jan 2026
At a glance
- Drugs CYB 004 (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
Most Recent Events
- 09 Jan 2026 According to Helus Pharma media release,topline data readout from this trial expected in Q1 2026
- 09 Jan 2026 New trial record